Literature DB >> 21166497

Angiogenic activity of mesenchymal stem cells in multiple myeloma.

Xiaofang Wang1, Zhiqing Zhang, Cheng Yao.   

Abstract

The pathophysiology of multiple myeloma-induced angiogenesis is complex and involves both direct production of angiogenic cytokines by plasma cells and their induction within the microenvironment. In this research, we investigated whether mesenchymal stem cells participated in inducing the angiogenic response in multiple myeloma, and explored the mechanism by which MSCs influence myeloma angiogenesis. We detected the concentration of angiogenic factors (bFGF, HGF, and VEGF) in the conditioned medium of mesenchymal stem cells and the capillary formation ability of mesenchymal stem cells in vitro. We found that conditioned medium of MSCs derived from MM significantly promoted the proliferation, chemotaxis, and capillary formation of human umbilical vein endothelial cells compared with that from normal donors. ELISA and RT-PCR were used to detect the mRNA and protein levels of angiogenic factors (bFGF, HGF, and VEGF) in the conditioned medium. We found that mRNA and protein levels of angiogenic factors were elevated in MSCs from multiple myeloma compared with normal donors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21166497     DOI: 10.3109/07357907.2010.496758

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  12 in total

1.  Angiogenesis and multiple myeloma.

Authors:  Nicola Giuliani; Paola Storti; Marina Bolzoni; Benedetta Dalla Palma; Sabrina Bonomini
Journal:  Cancer Microenviron       Date:  2011-07-07

Review 2.  Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics.

Authors:  Antonio Garcia-Gomez; Fermin Sanchez-Guijo; M Consuelo Del Cañizo; Jesus F San Miguel; Mercedes Garayoa
Journal:  World J Stem Cells       Date:  2014-07-26       Impact factor: 5.326

3.  In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib.

Authors:  Xinxin Xu; Jiao Yang; Yu Tang; Junxia Li; Yan Zhu; Hua Lu; Xiaoming Fei
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

Review 4.  Mesenchymal stem cell secretome and regenerative therapy after cancer.

Authors:  Ludovic Zimmerlin; Tea Soon Park; Elias T Zambidis; Vera S Donnenberg; Albert D Donnenberg
Journal:  Biochimie       Date:  2013-06-05       Impact factor: 4.079

Review 5.  Biological aspects of angiogenesis in multiple myeloma.

Authors:  Eléonore Otjacques; Marilène Binsfeld; Agnes Noel; Yves Beguin; Didier Cataldo; Jo Caers
Journal:  Int J Hematol       Date:  2011-11-17       Impact factor: 2.490

6.  ILK promotes angiogenic activity of mesenchymal stem cells in multiple myeloma.

Authors:  Weipeng Zhao; Xiaoying Zhang; Li Zang; Pan Zhao; Yafang Chen; Xiaofang Wang
Journal:  Oncol Lett       Date:  2018-05-16       Impact factor: 2.967

7.  HIF-2α-ILK Is Involved in Mesenchymal Stromal Cell Angiogenesis in Multiple Myeloma Under Hypoxic Conditions.

Authors:  Xiaoying Zhang; Yinhui Xu; Hongbo Liu; Pan Zhao; Yafang Chen; Zhijie Yue; Zhiqing Zhang; Xiaofang Wang
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

8.  Mesenchymal stem cells from bone marrow regulate invasion and drug resistance of multiple myeloma cells by secreting chemokine CXCL13.

Authors:  Guihua Zhang; Faan Miao; Jinge Xu; Rui Wang
Journal:  Bosn J Basic Med Sci       Date:  2020-05-01       Impact factor: 3.363

9.  Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche?

Authors:  J E Noll; S A Williams; L E Purton; A C W Zannettino
Journal:  Blood Cancer J       Date:  2012-09-14       Impact factor: 11.037

Review 10.  Potential clinical applications of adult human mesenchymal stem cell (Prochymal®) therapy.

Authors:  Amit N Patel; Jorge Genovese
Journal:  Stem Cells Cloning       Date:  2011-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.